Search research articles
Contact Us
Filters
Showing results (31-40 of 224) with videos related to
Page
of 23
Sort By:
Expert Review of Hematology
|
November 14, 2012
Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?
Prithviraj Bose, Steven Grant
Blood
|
December 9, 2017
T-PLL: another check on the venetoclax list?
Prithviraj Bose, Marina Y Konopleva
Leukemia & Lymphoma
|
November 15, 2021
Novel strategies for challenging scenarios encountered in managing myelofibrosis
Prithviraj Bose, Ruben A Mesa
Cancer Cell
|
March 14, 2018
ORY-1001: Overcoming the Differentiation Block in AML
Prithviraj Bose, Marina Y Konopleva
Expert Opinion on Pharmacotherapy
|
July 27, 2024
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature
Anthony M Hunter, Prithviraj Bose
Clinical Lymphoma, Myeloma & Leukemia
|
August 21, 2024
SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis
Helen T Chifotides, Prithviraj Bose
Cancers
|
October 14, 2020
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
Prithviraj Bose, Lucia Masarova, Srdan Verstovsek
Pharmacology & Therapeutics
|
April 29, 2014
Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights
Prithviraj Bose, Yun Dai, Steven Grant
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|
October 11, 2019
Novel treatment strategies for myeloproliferative neoplasms
Prithviraj Bose, Lucia Masarova, Srdan Verstovsek
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2022
Disease Modification in Myelofibrosis: An Elusive Goal?
Pankit Vachhani, Srdan Verstovsek, Prithviraj Bose
Page
of 23
Search research articles
Search
Showing results (31-40 of 224) with videos related to
Sort By:
Page
of 23
Expert Review of Hematology
|
November 14, 2012
Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?
Prithviraj Bose, Steven Grant
Blood
|
December 9, 2017
T-PLL: another check on the venetoclax list?
Prithviraj Bose, Marina Y Konopleva
Leukemia & Lymphoma
|
November 15, 2021
Novel strategies for challenging scenarios encountered in managing myelofibrosis
Prithviraj Bose, Ruben A Mesa
Cancer Cell
|
March 14, 2018
ORY-1001: Overcoming the Differentiation Block in AML
Prithviraj Bose, Marina Y Konopleva
Expert Opinion on Pharmacotherapy
|
July 27, 2024
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature
Anthony M Hunter, Prithviraj Bose
Clinical Lymphoma, Myeloma & Leukemia
|
August 21, 2024
SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis
Helen T Chifotides, Prithviraj Bose
Cancers
|
October 14, 2020
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
Prithviraj Bose, Lucia Masarova, Srdan Verstovsek
Pharmacology & Therapeutics
|
April 29, 2014
Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights
Prithviraj Bose, Yun Dai, Steven Grant
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|
October 11, 2019
Novel treatment strategies for myeloproliferative neoplasms
Prithviraj Bose, Lucia Masarova, Srdan Verstovsek
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2022
Disease Modification in Myelofibrosis: An Elusive Goal?
Pankit Vachhani, Srdan Verstovsek, Prithviraj Bose
Page
of 23